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Expression
Highest expression found in brain followed by pituitary gland and kidney. Expression has also been reported in bladder, eye, heart, cervix, breast, head and neck tissues etc.
Localisation
Cytoplasmic (diffuse cytoplasmic distribution in resting cells and a colocalization with EGF receptor in endocytic vesicles after EGF stimulation).
Function
SH3GL2 is a presynaptic protein that binds to dynamin, a GTPase that is implicated in endo-cytosis and recycling of synaptic vesicles. SH3GL2 by its LPAAT activity may induce negative membrane curvature by converting an inverted cone shaped lipid to a cone shaped lipid in the cytoplasmic leaflet of the bilayer. Through this action, SH3GL2 works with dynamin to mediate synaptic vesicle invagination from the plasma membrane and fission. SH3GL2 in complex with CBL and CIN85 participates in activated EGF receptor (Stimulated by EGF) endocytosis from the membrane surface and its subsequent lysosomal degradation. The SH3 domain of SH3GL2 binds to a 24 amino acid proline rich domain (PRD) in the third intracellular loop of the G-protein coupled-1-adrenergic receptor. SH3GL2 overexpression increased isoproterenolinduced receptor inter-nalization by 25% and decreased coupling of receptor to the G-protein.
The SH3 domain of SH3GL2 also binds to a proline rich domain within the cytoplasmic tail of metalloprotease disintegrins, transmembrane glycoproteins acting in cell adhesion and growth factor signaling. SH3GL2 binds preferentially to the pro-form found in the trans-Golgi network. Therefore SH3GL2 binding may regulate intracellular transit and maturation of metalloprotease disintegrin. Rat germinal centre kinse-like kinase (rGLK), a serine/threonine cytosolic kinase, interacted with SH3GL2. rGLK modulated c-Jun N-terminal kinase (JNK) activity by phosphorylation and binds to the SH3 domain of SH3GL2 through a C-terminal proline rich domain. Coexpression of rGLK and full length SH3GL2 increased JNK activity two fold, whereas coexpression with the SH3 domain of SH3GL2 abrogated rGLK-induced JNK activation. SH3GL2, therefore, modulated the mitogen-activated protein kinase pathway through physical association with rGLK.
Homology
SH3GL2 contains a C-terminal SH3 domain, which shares 92% and 84% amino acid sequence homology with the SH3 domain of SH3GL3 and SH3GL1, respectively. The SH3 domain of SH3GL2 also shows high homology to the C-terminal SH3 domain of GRB2.
Mutations
Somatic
In SH3GL2, mutation in SH3 domain has only been reported.
Implicated in
Sporadic cancer
Disease
Reduced expressions of SH3GL2 due to different types of molecular alterations are involved in tumor formation in head and neck, breast and gastric tissues. Prognosis The prognostic significance of down regulation of SH3GL2 in sporadic tumors is not understood clearly. Cytogenetics Chromosomal deletions, chromosomal gain or amplification and chromosomal breakpoints are frequent. Oncogenesis LOH on 9p22 is one of the most frequent events identified in head and neck tumor, breast carcinoma, pituitary adenoma, neuroblastoma etc. However, promoter methylation appears to be another common mechanism of SH3GL2 inactivation.
Alzheimer disease
Disease
The increased expression level of SH3GL2 in neuron is linked to an increase in the activation of the stress kinase c-Jun N-terminal kinase with the subsequent death of the neuron. Prognosis SH3GL2 overexpression is now considered as a new indicator of the progression of Alzhemier disease.
Cytogenetics
Increase in aneuploidy or aberration, but chromosomal loss or gain in aneuploid cell was not specific. In some forms of Alzheimer disease, a specific type of aneuploidy-trisomy 21 mosaicism has been reported.
